|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
FGFR3-TACC3 fusion transcripts were identified by RNA-FISH and RT-PCR in mouse xenograft FFPE tissues using the human BC cell lines RT112 and RT4.
|
27930669 |
2016 |
|
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of endogenous FGFR3 impaired the activity of daidzein against bladder cancer, which suggested that the effect of daidzein was mainly mediated by FGFR3 pathway.
|
27268915 |
2016 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer.
|
27091807 |
2016 |
|
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Our findings are consistent with the results of the TCGA data set for the "squamous-like" subtype of bladder cancer (n = 85), which revealed reduced overall expression of FGFR1 and FGFR2 in tumors compared to normal tissue, while expression of FGFR3 remained high.
|
27669755 |
2016 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations of FGFR3 are a common and early event in bladder cancer.
|
25223521 |
2015 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
Activating point mutations and protein overexpression of fibroblast growth factor receptors (FGFRs), especially FGFR3, are frequent events in bladder cancer.
|
24898159 |
2015 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.
|
25809917 |
2015 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
This is a comprehensive genomic characterization of 40 urothelial bladder carcinoma (UBC) cell lines including information on origin, mutation status of genes implicated in bladder cancer (FGFR3, PIK3CA, TP53, and RAS), copy number alterations assessed using high density SNP arrays, uniparental disomy (UPD) events, and gene expression.
|
25997541 |
2015 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
When we examined detailed data on a prevalent occupational exposure associated with increased bladder cancer risk, straight metalworking fluids, we also observed statistically significant additive interaction for rs798766 (TMEM129-TACC3-FGFR3, P interaction = .02), with the interaction more apparent in patients with tumors positive for FGFR3 expression.All statistical tests were two-sided.
|
26374428 |
2015 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer.
|
25654736 |
2015 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this review was to overview the outcomes of different mutations in FGFR3 receptor in the context of BC.
|
26542242 |
2015 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
TP53 and FGFR3 Gene Mutation Assessment in Urine: Pilot Study for Bladder Cancer Diagnosis.
|
26254388 |
2015 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study.
|
26364695 |
2015 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
|
25657201 |
2015 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
As for FGFR3 in UCC, tumors with high FOXA1 expression have lower rates of progression than those with low expression (Log rank p=0.009).
|
25071007 |
2014 |
|
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Conversely, FGFR3 over-expression was recently found in 40 % of muscle invasive BC.
|
24880661 |
2014 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
The development and progression of BC rely on a very complex signaling network that involves many different receptors aside from FGFR3 and VEGFR2.
|
25284004 |
2014 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We further demonstrate that activating mutations in FGFR3 associated with both multiple myeloma and bladder cancer can modulate expression of genes that regulate NFκB signaling, and promote both NFκB transcriptional activity and cell adhesion in a manner dependent on TAK1 expression in both cancer cell types.
|
24466111 |
2014 |
|
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
|
24360661 |
2014 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
MMP-1 and MMP-10 mRNA and protein were downmodulated by FGFR3 shRNA and R3Mab in bladder cancer cell lines.
|
25326231 |
2014 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study demonstrated that FGFR3 mutations are closely related to low grade, early stage, and better survival among bladder cancer patients.
|
24634132 |
2014 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
|
24784839 |
2014 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic FGFR3 gene fusions in bladder cancer.
|
23175443 |
2013 |
|
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Bladder cancer cell lines were exposed to normoxic or hypoxic conditions and examined for the expression of FGFR3 by quantitative PCR (qPCR) and western blotting, and miR-100 by qPCR.
|
23778527 |
2013 |